Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy

Medical mystery at the AHA conference: A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or st…

Continue in Briflio to read, react, comment, and share.